Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial F Lublin, DH Miller, MS Freedman, BAC Cree, JS Wolinsky, H Weiner, ... The Lancet 387 (10023), 1075-1084, 2016 | 480 | 2016 |
Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis T Chitnis, DL Arnold, B Banwell, W Brück, A Ghezzi, G Giovannoni, ... New England Journal of Medicine 379 (11), 1017-1027, 2018 | 319 | 2018 |
First clinical study on ultra-high-field MR imaging in patients with multiple sclerosis: comparison of 1.5 T and 7T K Kollia, S Maderwald, N Putzki, M Schlamann, JM Theysohn, O Kraff, ... American Journal of Neuroradiology 30 (4), 699-702, 2009 | 229 | 2009 |
Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management AM Arvin, JS Wolinsky, L Kappos, MI Morris, AT Reder, C Tornatore, ... JAMA neurology 72 (1), 31-39, 2015 | 189 | 2015 |
CD4+ CD25+ FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis M Kumar, N Putzki, V Limmroth, R Remus, M Lindemann, D Knop, ... Journal of neuroimmunology 180 (1-2), 178-184, 2006 | 185 | 2006 |
Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS J Hobart, AR Blight, A Goodman, F Lynn, N Putzki Neurology 80 (16), 1509-1517, 2013 | 180 | 2013 |
Prevalence of migraine, tension‐type headache and trigeminal neuralgia in multiple sclerosis N Putzki, A Pfriem, V Limmroth, Ö Yaldizli, B Tettenborn, HC Diener, ... European Journal of Neurology 16 (2), 262-267, 2009 | 166 | 2009 |
Quality of life in 1000 patients with early relapsing–remitting multiple sclerosis N Putzki, J Fischer, K Gottwald, G Reifschneider, S Ries, A Siever, ... European journal of neurology 16 (6), 713-720, 2009 | 105 | 2009 |
Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells N Putzki, MK Baranwal, B Tettenborn, V Limmroth, E Kreuzfelder European neurology 63 (5), 311-317, 2010 | 102 | 2010 |
Kinesthesia is impaired in focal dystonia N Putzki, P Stude, J Konczak, K Graf, HC Diener, M Maschke Movement disorders 21 (6), 754-760, 2006 | 101 | 2006 |
Efficacy of natalizumab in second line therapy of relapsing–remitting multiple sclerosis: results from a multi‐center study in German speaking countries N Putzki, O Yaldizli, M Mäurer, S Cursiefen, S Kuckert, C Klawe, ... European journal of neurology 17 (1), 31-37, 2010 | 100 | 2010 |
Quality Assessment in Multiple Sclerosis Therapy (QUASIMS) A comparison of interferon beta therapies for relapsing-remitting multiple sclerosis V Limmroth, R Malessa, UK Zettl, J Koehler, G Japp, P Haller, W Elias, ... Journal of neurology 254, 67-77, 2007 | 87 | 2007 |
Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients N Putzki, Z Katsarava, S Vago, HC Diener, V Limmroth European Neurology 59 (3-4), 136-142, 2008 | 78 | 2008 |
Corpus callosum index and long-term disability in multiple sclerosis patients Ö Yaldizli, R Atefy, A Gass, D Sturm, S Glassl, B Tettenborn, N Putzki Journal of neurology 257, 1256-1264, 2010 | 75 | 2010 |
Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland N Putzki, Ö Yaldizli, R Bühler, G Schwegler, D Curtius, B Tettenborn European neurology 63 (2), 101-106, 2010 | 73 | 2010 |
Multiple sclerosis associated fatigue during natalizumab treatment N Putzki, Ö Yaldizli, B Tettenborn, HC Diener Journal of the neurological sciences 285 (1-2), 109-113, 2009 | 71 | 2009 |
The interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the … V Limmroth, N Putzki, NJ Kachuck Therapeutic Advances in Neurological Disorders 4 (5), 281-296, 2011 | 70 | 2011 |
Fatigue and progression of corpus callosum atrophy in multiple sclerosis Ö Yaldizli, S Glassl, D Sturm, A Papadopoulou, A Gass, B Tettenborn, ... Journal of neurology 258, 2199-2205, 2011 | 64 | 2011 |
Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis N Putzki, K Kollia, S Woods, E Igwe, HC Diener, V Limmroth European journal of neurology 16 (3), 424-426, 2009 | 58 | 2009 |
Relapsing neuromyelitis optica responsive to glatiramer acetate treatment. K Gartzen, V Limmroth, N Putzki European Journal of Neurology 14 (6), e12-3, 2007 | 56 | 2007 |